Anti-HIV therapy with antisense oligonucleotides and ribozymes: Realistic approaches or expensive myths?

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 2, 1996, Pages 159-165

  Akhtar, S ^a   Rossi, J J ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RIBOZYME;

DNA SYNTHESIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE;

EID: 0029784466     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.2.159     Document Type: Editorial

References (64)

1. Agrawal, S. (1992). Antisense oligonucleotides as antiviral agents. Trends in Biotechnology 10, 152-8.
2. Agrawal, S., Goodchild, J., Civeira, M. P., Thornton, A. H., Sarin, P. S. & Zamecnik, P. C. (1988). Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proceedings of the National Academy of Sciences USA 85, 7079-83.
3. Agrawal, S. & Tang, J. Y. (1992). GEM 91: an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Research and Development 2, 261-6.
4. Agrawal, S., Temsamani, J., Galbraith, W. & Tang, J. (1995a). Pharmacokinetics of antisense oligonucleotides. Clinical Pharmacokinetics 28, 7-16.
5. Agrawal, S., Zhang, X., Lu, Z., Hui, Z., Tamburin, J. M., Yan, J. et al. (1995b) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochemical Pharmacology, 50, 571-6.
6. Akhtar, S., Ed. (1995). Delivery Straitegies for Antisense Oligonuclegotide Therapeutics. CRC Press. Boca Raton, FL.
7. Akhtar, S., James, H. & Gibson, I. (1995a). Molecular DIY with hairpins and hammerheads. Nature Medicine, I, 300-2.
8. Akhtar, S. & Juliano, R. L. (1992). Cellular uptake and intracellular fate of antisense oligonucleotides. Trends in Cell Biology 2, 139-44.
9. Akhtar, S., Kole, R. & Juliano, R. L. (1991). Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sciences 49, 1793-801.
10. Akhtar, S., Routledge, A. R., Patel, R. & Gardiner, J., (1995b) Synthesis of mono- and di-mannoside phosphoramidite derivatives for solid-phase conjugation to oligonucleotides. Tetrahedron Letters, 36, 7333-6.
11. Altman, S. (1993). RNA enzyme directed gene therapy. Proceedings National Academy of Sciences USA 90, 10898-900.
12. Aurup, H., Heidenreich, O. & Eckstein, F. (1995). Stabilized RNA analogues for antisense and ribozyme applications. In Delivery Strategies for Antisense Oligonucleotide Therapeutics (Akhtar, S., Ed.). CRC Press. Boca Raton, USA
13. Bertrand, E. & Rossi, J. J. (1994). Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein Al. EMBO Journal 13, 2904-12.
14. Berzal-Herranz, A., Joseph, S., Chowrira, B. M., Butcher, S. E. & Burke, J. M. (1993). Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO Journal 12, 2567-73.
15. Bongartz, J. P., Aubertin, A. M., Milhaud, P. G. & LeBleu, B. (1994). Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Research 22, 4681-8.
16. Culabretta, B. (1991). Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Research 51, 4505-510.
17. Cech, T. R. (1992). Ribozyme engineering. Current Opinion in Structural Biology 2, 605-9.
18. Chang, P., Cantin, E. M., Zaia, J. A., Ladne, P. A., Stephens, D. A., Sarver, N. (1990). Ribozyme mediated site-specific cleavage of the HIV-1 genome. Clinical Biotechnology 2, 23-31.
19. Chen, C.-J , Banerjea, A. C., Harmison, G. G., Haglund, K. & Schubert, M. (1992). Multitargetribozyme directed to cleave at up to nine highly conserved HIV-I env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Research 20, 4581-9.
20. Crisell, P., Thompson, S. & James, W. (1993). Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Research 21, 5251-5.
21. Crooke, S. T. & LeBleu, B. (1993). Antisense Research and Applications. CRC Press, Boca Raton, FL.
22. Dropulic, B., Lin, N. H., Martin, M. A. & Jeang, K.-T. (1992). Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. Journal of Virology 66, 1432-41.
23. Embretson, J., Zupancic, M., Ribas, J. L., Burke, A., Racz, P., Tenner-Racz, K. et al. (1993). Massive covert infection of helper T lymphocytes and macrophages by HIV-1 during the incubation period of AIDS. Nature 362, 359-62.
24. Fauci, A. S. (1993). Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262, 1011-8.
25. Flory, C. M., Pavco, P. A., Jarvis, T. C., Lesch, M. E., Wincott, F. E., Biegelman, L. et al. (1996). Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proceedings of the National Academy of Sciences USA 93, 754-8.
26. Goldstein, S., Engle, R., Olmsted, R. A., Hirsch, V. M. & Johnson, P. R. (1990). Detection of SIV antigens by HIV-1 antigen capture immunoassays. Journal of AIDS 3, 98-102.
27. Herschlag, D., Khosia, M., Tsuchihashi, Z. & Karpel, R. L. (1994). An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis. EMBO Journal 13, 2913-24.
28. Hudson, A. J., Lewis, K. J., Rao, V. M. & Akhtar, S. (1996). Biodegradable polymers for the sustained exogenous delivery of ribozymes. International Journal of Pharmaceutics, 136, 23-9.
29. Iversen, P. L., Mata, J., Tracewell, W. G. & Zon, G. (1994). Pharmacokinetics of antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Research and Development 4, 43-52.
30. Larder, B. A., Darby, G. & Richman, D. D. (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-4.
31. Lewis, K. J., Irwin, W. J. & Akhtar, S. (1995). Biodegradable poly (L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. Journal of Controlled Release 37, 173-83.
32. Lo, K. M. S., Biasolo, M. A., Dehni, G., Palu, G. & Haseltine, W. A. (1992). Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190, 176-83.
33. Marschall, P., Thomson, J. B. & Eckstein, F. (1994). Inhibition of gene expression with ribozymes. Cellular and Molecular Neurobiology 14, 523-38.
34. Matsukura, M. (1992). Regulation of HIV gene expression by antisense oligonucleotides. In Antisense RNA and DNA. (Murray. J. A. H., Ed.), pp. 285 304. Wiley Liss.
35. Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J. S. et al. (1987). Phosphorothioate analogos of oligodeoxynucleotides: inhibitors of replication and cytopathic effects on human immunodeficiency virus. Proceedings of the National Academy of Sciences USA 84, 7706-10.
36. Milligan, J. F., Matteucci, M. D. & Martin, J. C. (1993). Current concepts in antisense drug design. Journal of Medicinal Chemistry 36, 1923-37.
37. Monsigny, P., Roche, A. C., Midoux, P. & Mayer, R. (1994). Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes. Advanced Drug Delivery Reviews 14, 1-24.
38. Oberhauser, B., Plank, C. & Wagner, E. (1995). Enhancing endosomal exit of nucleic acids using pH-sensitive viral fusion peptides. In Delivery Strategies for Antisense Oligonucleotide Therapeutics (Akhtar, S., Ed.), CRC Press, Boca Raton, FL.
39. Ojwang, J. O., Hampel, A., Looney, D. J., Wong-Staal, F. & Rappaport, J. (1992). Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proceedings of I he National Academy of Sciences USA 89, 10802-6.
40. Pantaleo, G., Graziosi, C., Demarest, G. F., Butini, L., Montroni, M. Fox, C. H. et al. (1993). HIV-1 infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-8.
41. Rossi, J. J. (1992). Ribozymes. Current Opinions in Biotechnology 3, 3-7.
42. Sands, H., Gorey-Feret, L. J., Cocuzza, A. J. Hobbs, F. W., Chidester, D. & Trainor, G. L. (1994). Biodistribution and metabolism of internally 3H-labelled oligonucleotides I. Comparison of a phosphodiester and a phosphorothioate. Molecular Pharmacology 45, 932-43.
43. Sarmiento, U., Perez, J. R., Becker, J. M. & Narayanan, R. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-I mice. Antisense Research and Development 4, 99-107.
44. Sarver, N., Cantin, E. M., Chang, P. S., Zaia, J. A., Ladne, P. A., Stephens, D. A. et al. (1990). Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-5.
45. Sharma, H. W. & Narayanan, R. (1995). The therapeutic potential of antisense oligonucleotides. Bioessays 17, 1055-63.
46. Stein, C. A. & Cheng, Y.-C. (1993). Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 26, 1004-12.
47. Stein, C. A., Cleary, A. M. Yakubov, L., Lederman, S. (1993). Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virustype-l gp120. Antisense Research and Development, 3, 19-31.
48. Sullenger, B. A. & Cech, T. R. (1993). Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262, 1566-9.
49. Symons, R. (1992). Small catalytic RNAs. Annual Reviews in Biochemistry 62, 641-71.
50. Tidd, D. M., (1990). A potential role of antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy, Anticancer Research 10, 1169-82.
51. Tsuchilhashi, Z., Khosla, M. & Herschlag, D. (1993). Protein enhancement of hammerhead ribozyme catalysis. Science 262, 99-102.
52. Vaishnav, Y. N. & Wong-Staal, F. (1991). The biochemistry of AIDS. Annual Reviews in Biochemistry 60, 577-630.
53. Wagner, R. (1995). Toward a broad-based antisense technology. Antisense Research and Development 5, 113-4.
54. Wagner, R. W. (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-5.
55. Weerasinghe, M., Liem, S. E., Asad, S., Read, S. E. & Joshi, S. (1991). Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. Journal of Virology 65, 5531-4.
56. Wickstrom, E. (1995). Nucelease-resistant DNA therapeutics, In Delivery Strategies for Antisense Oligonucleotide Therapeutics (Akhlar, S., Ed.), CRC Press, Boca Raton, FL.
57. Yamada, O., Yu, M, Yee, J.-K., Kraus, G., Looney, D. & Wong-Staal, F. (1994). Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type I. Gene Therapy 1, 38-45.
58. Yu, M., Ojwang, J., Yamada, O., Hampel, A., Rappaport, J., Looney, D. et al. (1993). A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type I. Proceedings of the National Academy of Sciences USA 90, 6340-4.
59. Yu, M., Poeschla, E. & Wong-Staal, F. (1994). Progress towards gene therapy for HIV-1 infection. Gent Therapy 1, 13-26.
60. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A. & Chen, I. S. (1990). HIV-I entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-22.
61. Zamecnik, P. C., Goodchild, J., Taguchi, Y. & Sarin, P. S. (1986). Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proceedings of the National Academy of Sciences USA 83, 4143-6.
62. Zhang, R., Diasio, R. B., Lu, Z., Liu, T., Jiang, Z., Galbraith, W. et al. (1995a). Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM91) developed as a therapeutic agent for human immunodeficiency virus lype-1. Biochemical Pharmacology 49, 929-39.
63. Zhang, R., Yan, J., Shahinian, H., Amin, G., Lu, Z., Liu, T. et al. (1995b) Pharmacokinetics of an anti-HIV antisense oligodeoxynucleotide phosphorothioate (GEM91) in HIV-infected subjects. Clinical Pharmacology and Therapeutics, 58, 44-53.
64. Zhou, C., Bahner, I. C., Larson, G. P., Zaia, J. A., Rossi, J. J. & Kohn, D. B. (1994). Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149, 33-9.